Mereo BioPharma (MREO) Return on Capital Employed (2024 - 2026)
Mereo BioPharma (MREO) posted quarterly Return on Capital Employed of 101.57% for Q1 2026, down 2654.0% year-over-year from 3.98% in Q1 2025, and down 15.12% quarter-over-quarter from 88.23% in Q4 2025.
Mereo BioPharma (MREO) Return on Capital Employed (2024 - 2026) Analysis & Trends
Mereo BioPharma (MREO) has reported Return on Capital Employed for 3 consecutive years, with 101.57% the latest figure, recorded in Q1 2026.
- In Q1 2026, Return on Capital Employed fell 2654.0% year-over-year to 101.57%; the TTM figure through Mar 2026 stood at 101.57% (down 2654.0% YoY), while the FY2025 annual figure was 70.55%, up 1169.0% from the prior year.
- Return on Capital Employed eased to 101.57% in Q1 2026 per MREO's latest filing, from 88.23% in the prior quarter.
- Across five years, Return on Capital Employed topped out at 50.13% in Q3 2024 and bottomed at 101.57% in Q1 2026.
- Historically, Return on Capital Employed has averaged 74.66% across 3 years, with a median of 75.03% in 2025.
- On a YoY basis, Return on Capital Employed climbed as much as 1578 bps in 2025 and fell as far as 4006 bps in 2025.
- Mereo BioPharma's Return on Capital Employed stood at 68.92% in 2024, then slipped by 28 bps to 88.23% in 2025, then declined by 15 bps to 101.57% in 2026.
- Business Quant data shows MREO's Return on Capital Employed at 101.57% in Q1 2026, 88.23% in Q4 2025, and 90.19% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -38.20% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 13.68% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 26.09% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -6.85% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -50.93% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 7.88% |
| 10 | Mereo BioPharma | 47.39 Mn | 47.39 Mn | - | -106.92% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -106.92% |
| Mar 31, 2026 | -101.57% |
| Dec 31, 2025 | -88.23% |
| Sep 30, 2025 | -90.19% |
| Jun 30, 2025 | -80.02% |
| Mar 31, 2025 | -75.03% |
| Dec 31, 2024 | -68.92% |
| Sep 30, 2024 | -50.13% |
| Jun 30, 2024 | -64.24% |
| Mar 31, 2024 | -53.58% |